Healthcare, Journal Year: 2024, Volume and Issue: 12(22), P. 2275 - 2275
Published: Nov. 14, 2024
There is a lack of empirical studies out-of-pocket health expenditures associated with dyslipidemias, which are major cardiovascular risk factors, especially in underrepresented admixed populations. The study investigates associations costs lipid traits, GWAS-derived genetic scores (GRSs), and other cardiometabolic factors.
Language: Английский
Circulation, Journal Year: 2024, Volume and Issue: 149(8)
Published: Jan. 24, 2024
BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, obesity) factors (cholesterol, blood pressure, glucose control, metabolic syndrome) that contribute health. AHA Disease Stroke Statistical Update presents latest data on a range major clinical circulatory disease conditions (including brain health, complications pregnancy, kidney congenital rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary cardiomyopathy, failure, valvular venous thromboembolism, peripheral artery disease) associated outcomes quality care, procedures, economic costs). METHODS: AHA, through its Epidemiology Prevention Statistics Committee, continuously monitors evaluates sources stroke United States globally provide current information available annual review published literature year before writing. 2024 is product full year’s worth effort 2023 by dedicated volunteer clinicians scientists, committed government professionals, staff members. strives further understand help heal problems inflicted structural racism, public crisis can significantly damage mental perpetuate disparities access education, income, housing, several other vital healthy lives. This edition includes additional global data, as well monitoring benefits population, an enhanced focus equity across key domains. RESULTS: Each chapters focuses different topic statistics. CONCLUSIONS: represents critical resource for lay public, policymakers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.
Language: Английский
Citations
934
JACC Heart Failure, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
1
Medical Care, Journal Year: 2025, Volume and Issue: unknown
Published: April 24, 2025
Importance: Little is known about the extent to which patient self-perception of care experience associated with costs, especially for people Alzheimer disease and related dementias (ADRD). Objective: This study explores relationship between self-reported quality measures Medicare costs examines whether ease obtaining prescribed medications reduced overall focusing on beneficiaries ADRD. Design, Setting, Participants: In this cross-sectional study, Beneficiary Summary File data from 2018, 2019, 2021 were linked Consumer Assessment Health Care Providers Systems (CAHPS) Survey using beneficiary IDs. The sample included community-dwelling fee-for-service beneficiaries. Exposures: Five used as key exposure variables: (1) beneficiary’s rating health care, (2) getting care/tests/treatment through plan, (3) doctor always explained, listened, respected, spent enough time patient, (4) medications, (5) talked all prescription medicines was taking. Main Outcome Measure: Annual total payments per person. Results: 230,617 FFS aged 65 older, including 16,452 Among beneficiaries, 53% females (vs. 56% ADRD beneficiaries), a mean (SD) age 75.8 (SD 7.27) years [vs. 82.5 7.97) beneficiaries]. Fully adjusted analyses showed significant negative associations per-capita payments, more pronounced cost reductions among patients Specifically, who reported it easy get had $1,922.0 (95% CI, -$3304.8 -$539.2), while those $2964.5 -$4518.8 -$1410.1). addition, that doctors discussed experienced $2299.7 -$3800.5 -$799.0) in medicare costs. Conclusion Relevance: Our findings suggest high-quality not necessarily high Meanwhile, access needed drugs, effective communication medication critical improving reducing
Language: Английский
Citations
0
Circulation Heart Failure, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 28, 2025
High out-of-pocket costs and financial toxicity related to heart failure treatment are substantial concerns. Two of 4 pillars guideline-directed medical therapy for with reduced ejection fraction, example, carry high that may attenuate their uptake. Furthermore, rarely occurs in isolation. Many patients have other comorbidities require treatment, further driving up patients’ costs. Developing plans improve mortality without subjecting can be challenging several reasons. First, accrue from multiple domains depend on a variety insurance pharmacy-related factors make determining patient-specific cost estimates complicated. Second, strategies mitigate involve health policy-level interventions patient-level interventions. These own unique sets challenges. Third, integrating into shared decision-making requires nuanced discussions about whether is worth the cost. Though has been advocated, there little data how best conduct these discussions. Health policies like Inflation Reduction Act 2022 provide relief some patients, efforts transparency potential beneficial. Over long term, policy solutions such as value-based design patient engagement emphasize enhancing important yield durable results.
Language: Английский
Citations
0
JACC Heart Failure, Journal Year: 2024, Volume and Issue: 12(7), P. 1238 - 1241
Published: June 12, 2024
Language: Английский
Citations
2
PharmacoEconomics, Journal Year: 2024, Volume and Issue: 42(11), P. 1279 - 1286
Published: Aug. 21, 2024
Language: Английский
Citations
2
JAMA, Journal Year: 2023, Volume and Issue: 330(17), P. 1619 - 1619
Published: Sept. 20, 2023
This Viewpoint discusses how the price negotiation for certain drugs under Inflation Reduction Act will provide a unique opportunity to enhance access therapies older patients with cardiovascular conditions and diabetes.
Language: Английский
Citations
5
Pharmacy, Journal Year: 2023, Volume and Issue: 11(6), P. 187 - 187
Published: Dec. 17, 2023
In this review, we examine the impact of Inflation Reduction Act (IRA) 2022 on pharmaceutical drugs in United States, drawing a diverse range sources to understand perceptions multiple stakeholders and professionals. Findings suggest that Act, while aiming control price inflation, has had multifaceted sector. Stakeholders, including companies, healthcare providers, patient advocacy groups, policymakers, offered varied perspectives: some laud for its potential controlling runaway drug prices making more accessible, others raise concerns about possible reductions innovation, disruptions supply chains, sustainability smaller companies. The review identified four underlying constructs (themes) literature surrounding stakeholders' IRA's upon prescription drugs: pricing and/or dictation issues, topics related patent law pharmaceuticals, processes (2022) rules regulations, threats industry concerning research development future medications. complex interplay Act's implications underscores importance ongoing assessment iterative policy refinements as implementation endures.
Language: Английский
Citations
5
Journal of Managed Care & Specialty Pharmacy, Journal Year: 2023, Volume and Issue: 30(1), P. 34 - 42
Published: Dec. 28, 2023
Glucagon-like peptide 1 receptor agonists (GLP1-RAs) and sodium glucose cotransporter 2 inhibitors (SGLT2is) have proven benefits in patients with type diabetes mellitus related to decreasing cardiovascular events heart failure hospitalizations as well preventing the progression of kidney disease. This led American Diabetes Association (ADA) update their guidelines 2022 recommend GLP1-RAs SGLT2is potential first-line options cardiorenal conditions. Formulary restrictions, such step therapy prior authorizations, can limit access these beneficial medications.
Language: Английский
Citations
3
Circulation Cardiovascular Quality and Outcomes, Journal Year: 2023, Volume and Issue: 16(10)
Published: Oct. 1, 2023
Language: Английский
Citations
2